For ingredient suppliers, manufacturers and technology partners: how an engagement would run, who would own the results, what published license rates look like, and why the regulatory category limits any agreement. Not legal advice.
Status. EUTECNIQ Sciences is a company in formation. It has no customers, licenses or patents of its own. The founder's patents are assigned to a prior employer and are not EUTECNIQ assets.
Models can be combined, for example development services followed by a supply agreement.
Paid work on a defined technical question: characterization, formulation, stability, regulatory strategy or process development.
EUTECNIQ would supply a qualified ingredient to an agreed specification, with lot documentation and change control.
EUTECNIQ would distribute or represent an international supplier's ingredient in the United States. See the five distribution models.
Shared development of a new or improved ingredient, formulation or process, with shared cost and agreed rights.
A license to a defined process or formulation know-how, with technology transfer to the licensee's site.
Licensing or sale of patents, data packages or trademarks EUTECNIQ might create in future. EUTECNIQ holds none today.
| Model | EUTECNIQ would deliver | The partner would provide | Payment basis | Proposed default for new results |
|---|---|---|---|---|
| Development services | Study plan, data, reports, transfer dossier | Material, target profile, prior data, decisions at gates | Fee by stage | Customer owns project-specific results |
| Supply agreements | Lots to specification with documentation | Forecasts, specification sign-off, purchase orders | Price per kilogram | No transfer |
| Distributor arrangements | U.S. documentation, sales, import handling | Product, technical data, quality agreement | Margin or commission | Set by contract |
| Co-development | Science, regulatory and application work | Process access, pilot material, cost share | Shared cost, milestones, royalties | Allocated in writing by field or party |
| Process licensing | Technology package and transfer support | Receiving site, batches, royalty reports | Upfront, milestones, royalty | Licensor keeps ownership |
| IP commercialization | License or assignment of defined rights | Development and commercialization effort | Upfront, milestones, royalties or price | Per the instrument |
Detailed gate criteria are in the stage-gate detail further down.
| Step | What would happen | Decision at the end |
|---|---|---|
| 1. Inquiry and NDA | Non-confidential summary; fit with EUTECNIQ's proposed capabilities and partners; mutual NDA | Proceed to a feasibility proposal, or decline |
| 2. Technical feasibility | Identity can be established; bench data on real lots; first cost-of-goods and regulatory-category screen | Is the product technically and legally plausible at a viable cost? |
| 3. Commercial terms | Engagement model, scope, payments, background and new IP, data and reference rights | Signed agreement, or stop with the feasibility report |
| 4. Development and validation | Process and formulation development; analytical methods validated; specifications drafted; stability started | Do representative batches meet draft specifications? |
| 5. Regulatory and quality readiness | Notification or GRAS work where required; label and claims review; supplier qualification; quality agreement | Is every legal and quality prerequisite for launch met? |
| 6. Commercial transfer | Transfer dossier; analytical method transfer; confirmation batches at the commercial site; comparability review | Can the receiving site meet the specification on its own batches? |
| 7. Launch and lifecycle | Routine supply; complaint and adverse-event handling; change control; annual review | Renew, improve, extend to new uses or markets, or retire |
Either list missing an item is a reason to hold a gate.
| Section | Contents | Used for |
|---|---|---|
| Product definition | Composition, intended use, claims boundaries, target product profile | Confirms what is being transferred |
| Specifications | Every limit with its method and reason; reference standards | Release decisions at the receiving site |
| Analytical methods | Methods, validation or verification records, transfer protocol with acceptance criteria | Analytical method transfer |
| Process description | Unit operations, critical parameters and ranges, equipment class, scale-up notes | Confirmation batches |
| Materials and suppliers | Raw-material specifications, approved suppliers, qualification records | Supplier and material qualification |
| Stability | Protocol, data, and the basis and limits of the retest date or shelf life | Dating and storage at the receiving site |
| Regulatory status file | Category, notifications or conclusions, claims plan, rights to reference filings | Lawful marketing by the receiving party |
| Safety file | Evidence summary and limitations at the intended intake | The receiving party's own safety responsibility |
| Change and comparability history | Changes made and the data that supported them | Future change control |
| Rights schedule | Background and new IP, licenses granted, field, territory and term | Freedom to use what is transferred |
| Open risks | Known issues and recommended controls | Receiving-site risk register |
Background IP is what each party brings. Foreground IP is what the project creates. Improvements are changes to one party's background technology made during the project.
| Item | Proposed default | Reason |
|---|---|---|
| Background IP | Stays with its owner; licensed to the other party only as needed for the project, non-exclusively and for the project term | Neither party loses what it brought |
| New results from paid development services | Customer owns project-specific results; EUTECNIQ keeps general methods and know-how | The customer paid for the specific answer |
| New results from co-development | Allocated by field of use, or jointly owned under a written agreement on use, licensing, enforcement and cost | Joint ownership without terms lets each owner exploit freely |
| Improvements to background technology | Belong to the background owner, with a license back where the other party needs them | Keeps each platform whole |
| Data and regulatory files | Owned by the party that paid; any right to reference them in a filing granted in writing | Data are protected by contract, not by patent |
| Publications | Only with both parties' consent, after a review period | Publication before filing can destroy patentability |
Patents and applications are assignable by an instrument in writing, and exclusive rights can be granted for the whole or part of the United States.
35 U.S.C. 261Without an agreement to the contrary, each joint owner of a U.S. patent may make, use, sell or import the invention without the other owners' consent and without accounting to them.
35 U.S.C. 262A naturally occurring substance is not patent-eligible merely because it has been isolated. Protection for botanicals rests on engineered formulations, processes and know-how.
569 U.S. 576 (2013)Weakest fit for botanicals. A naturally occurring DNA segment "is a product of nature and not patent eligible merely because it has been isolated" (Myriad, 2013). USPTO compares a claimed nature-based product with its closest natural counterpart and asks whether its characteristics are markedly different (MPEP 2106.04(c)).
569 U.S. 576 · MPEP 2106.04(c)A defined composition (for example a self-emulsifying system) with data showing what it does. It must still be new and non-obvious, and claims need written support and enablement. Term: 20 years from the earliest non-provisional or PCT filing.
35 U.S.C. 101–103, 112, 154Infringement happens inside a competitor's plant, so it is hard to detect. U.S. law also treats importing, selling or using in the U.S. a product made abroad by a U.S.-patented process as infringement, unless the product is materially changed afterwards.
35 U.S.C. 271(a), 271(g)Relevant mainly to drug programs. A claim that states a natural correlation and adds routine steps is not eligible: the Court required more than "the law of nature while adding the words 'apply it'" (Mayo, 2012). A supplement label that makes a disease claim is regulated as a drug unless it is an authorized health claim.
566 U.S. 66 · 21 CFR 101.93(f)No fixed term; protection lasts while the information stays secret and is protected by reasonable measures. Federal civil action for misappropriation under 18 U.S.C. 1836 (added May 11, 2016), filed within 3 years of discovery. A notification to FDA becomes public after 90 days except trade-secret and confidential commercial information.
18 U.S.C. 1836 · 21 CFR 190.6(e)Not a patent right: value comes from contracts that define who may use or reference the data, and from the cost of recreating it. FDA's master-file mechanism for new dietary ingredients is a 2024 draft guidance, not a final rule (see NDIN).
Contract rights Draft guidance35 U.S.C. 261 and 262 (Cornell LII, accessed October 22, 2026); Association for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013). Not legal advice. Protection types, patent term and freedom to operate are in the IP detail below.
| Category | Set by | What the category requires | Sources |
|---|---|---|---|
| Dietary supplement | Ingested product labeled as a dietary supplement and not represented as a conventional food (21 U.S.C. 321(ff)) |
| 21 U.S.C. 321(ff), 379aa-1; 21 CFR 111, 190.6, 101.93 |
| Conventional food | Food whose every ingredient is GRAS for its intended use or an approved food additive (21 U.S.C. 321(s)) |
| 21 U.S.C. 321(s); 21 CFR 170.30, 170 subpart E, 117; 91 FR 51834 |
| Food additive (petition needed) | A food ingredient that is not GRAS for its intended use is a food additive (21 U.S.C. 321(s), 348) |
| 21 U.S.C. 321(s), 348 |
| Cosmetic | Applied to the body to cleanse, beautify, promote attractiveness or alter appearance (21 U.S.C. 321(i)) |
| MoCRA (enacted December 29, 2022); FDA, Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?) |
| OTC monograph drug | Intended to diagnose, cure, mitigate, treat or prevent disease, within a final OTC monograph (21 U.S.C. 321(g)(1)(B), 355h) |
| 21 U.S.C. 355h; FDA OTC monograph reform page; 21 CFR 210/211 |
| New drug: IND, then NDA | Drug intended use not covered by a monograph (21 U.S.C. 321(g)(1)) |
| 21 CFR 312, 314; FDA Botanical Drug Development guidance (2016); 35 U.S.C. 156 |
One botanical ingredient can be a supplement, food, cosmetic or drug ingredient, depending on the product and what is said about it. A license or supply agreement does not change the category's rules. Status as of October 2026. The new-dietary-ingredient route is detailed on the NDIN page.
21 U.S.C. 321(s)(6): ingredients of dietary supplements are excluded from the food-additive definition only for supplement use; 21 CFR 170.30: GRAS status is for the substance "under the conditions of its intended use"; 21 CFR 210.1, 211.1 and 111.1 (scope). See international market access for non-U.S. rules.
| Industry sample | Agreements | Mean | Median | 95% interval of the mean | Within 2–5% |
|---|---|---|---|---|---|
| Pharmaceutical | 90 | 5.66% | 4.375% | 4.75–6.57% | 46 |
| Chemical | 21 | 3.70% | 3% | 2.82–4.57% | 11 |
| Medical device (summary only; not drawn) | 77 | 4.35% | 4% | 3.71–5.00% | – |
Pharmaceutical rates, % (sorted): 0.5, 1, 1.375, 1.5, 1.5, 1.75, 1.75, 2, 2, 2, 2, 2, 2.25, 2.25, 2.5, 2.5, 2.5, 2.5, 2.75, 2.9, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3, 3.25, 3.25, 3.3, 3.5, 3.5, 3.5, 3.75, 4, 4, 4, 4, 4, 4, 4, 4.25, 4.5, 4.5, 5, 5, 5, 5, 5, 5, 5.125, 5.25, 5.5, 6, 6, 6, 6, 6, 6, 6, 6.25, 7, 7, 7, 7, 7, 7, 7, 7.5, 8, 8, 8, 8.5, 9, 10, 10, 10, 10, 10, 10, 12.5, 13, 14.25, 17.5, 20, 20, 25
Chemical rates, % (sorted): 0.75, 1, 1, 1.875, 2.5, 2.5, 3, 3, 3, 3, 3, 3, 3, 5, 5, 5.5, 6, 6, 6, 6.5, 7
Rules of thumb are not evidence of a royalty. The Federal Circuit held that the 25 percent rule of thumb is "a fundamentally flawed tool for determining a baseline royalty rate in a hypothetical negotiation" (Uniloc v. Microsoft). Royalty stacking arises "when multiple patents read on a single product" (Lemley and Shapiro 2007).
Holdings and literature verifiedUniloc USA, Inc. v. Microsoft Corp., 632 F.3d 1292, 1315 (Fed. Cir. Jan. 4, 2011); Lemley MA, Shapiro C. Patent Holdup and Royalty Stacking. 85 Tex L Rev 1991 (2007). Not legal advice.
Royalty income is a rate applied to a defined base, such as net sales of the licensed product, plus any upfront fee and milestones. When several patents read on one product, royalties stack; anti-stacking clauses let the licensee credit part of what it pays others, down to a contractual floor.
| Function | Discovery | Feasibility | Development | Validation | Launch | Lifecycle |
|---|---|---|---|---|---|---|
| Science | Authenticated candidate, constituent profile, activity hypothesis Voucher-backed identity, a first chemical profile and a stated hypothesis about what the ingredient should do and at what exposure. | Extraction route, marker choice, first stability look Bench extraction across several raw-material lots; markers chosen for identity and strength; early stress testing to find weak points. | Optimized process and formulation; methods validated Design-of-experiments optimization, formulation work and validation of the analytical methods that will release product. | Specifications confirmed on representative batches Batches made the way commercial lots will be made, tested against draft specifications, with stability studies running. | Release testing and method support Routine testing handed to quality control; scientific support for investigations of out-of-specification results. | Ongoing stability; change-impact studies Stability commitments continue; any change to source, process or formulation is assessed before release. |
| Regulatory | Category screen: food, supplement, cosmetic or drug Intended use and claims decide the legal category (see Regulatory pathway). | Pathway decision; NDI or GRAS status; gap list Whether the ingredient is a new dietary ingredient, GRAS for food use, or neither; a costed list of evidence gaps. | Safety dossier built; claims plan drafted Evidence package scaled to the gaps (Safety & NDIN tab); wording of intended claims checked against the rules. | NDIN filed ≥ 75 days before marketing, or GRAS conclusion 21 CFR 190.6 when a notification is required; for food use, a documented GRAS conclusion or a notice under 21 CFR 170 subpart E. | Label review; 30-day notice of structure/function claims 21 CFR 101.93: notify FDA no later than 30 days after first marketing a supplement that carries a structure/function statement. | Serious adverse events reported in 15 business days 21 U.S.C. 379aa-1 for dietary supplements; tracking of guidance and rule changes. |
| Quality | Identity method plan with orthogonal techniques For example HPTLC plus LC-MS, chosen before material is bought in quantity. | Supplier assessment begins; risk assessment Hazards in the supply chain and the process ranked so that testing and controls follow risk. | Draft specifications; method validation Limits for identity, strength, composition and contaminants, with the reason for each limit. | Specifications approved; suppliers qualified Part 111 specifications approved by quality control; supplier certificates relied on only after qualification (21 CFR 111.75). | Independent QA release of each lot Release against approved specifications under 21 CFR Part 111 (supplements) or Part 117 (food). | Complaints, CAPA, change control, annual review Signals from complaints and trends feed corrective actions and controlled changes. |
| Manufacturing | Process concept and equipment class Which unit operations the product will need, and whether the planned facility has them. | Bench runs; scale-up risks named Heat-transfer, mass-transfer and mixing limits that can change at scale are listed early. | Pilot runs; critical parameters ranged Parameters that move quality attributes are identified and given operating ranges. | Confirmation batches at commercial scale The process runs at scale within its ranges and meets specifications. | Commercial production; capacity plan Scheduling, materials and capacity matched to signed demand. | Yield and cost improvement under change control Improvements made only through documented, assessed changes. |
| Commercial | Customer problem and target product profile What the buyer needs, in measurable terms: dose, format, documentation and price range. | Customer interviews; price and volume hypotheses Evidence that someone will buy, before development money is committed. | Samples to lead customers; supply terms drafted Customer feedback on real material; draft supply and quality terms. | Customer qualification of ingredient and supplier Customers' own quality teams audit and approve the supplier and the material. | Supply agreements; technical support Signed volumes and prices; application support for formulators. | Account expansion; new formats and markets Reorders, new applications and new regions, each checked against its own rules. |
| Legal & IP | Invention log; data-ownership terms set Ownership of data and inventions agreed with partners before work starts. | Prior-art search; freedom-to-operate screen Early look at patents that could block the product in launch countries. | Provisional or PCT filings; trade-secret controls File on engineered features backed by data; keep process know-how secret where filing would disclose it. | Freedom-to-operate opinion; license terms Written opinion from patent counsel for the launch markets; licenses where needed. | Contracts in force; enforcement plan Supply, quality and license agreements signed; monitoring for infringement. | Prosecution, maintenance, license audits Patents prosecuted and maintained; royalty reports audited. |
| Gate | Deliverables brought to the gate | Must meet (any miss is a kill or recycle) | Should meet (scored, traded off) |
|---|---|---|---|
| G1 Idea screen Discovery → Feasibility |
|
|
|
| G2 Go to development Feasibility → Development |
|
|
|
| G3 Go to validation Development → Validation |
|
|
|
| G4 Go to launch Validation → Launch |
|
|
|
| G5 Post-launch review Launch → Lifecycle |
|
|
|
Stage-Gate, described by Robert Cooper in 1990, separates the work (stages) from the decisions (gates). EUTECNIQ's proposed must-meet criteria reject a candidate early if identity cannot be established, a hazard is known at the intended exposure, an interaction is unmanageable or a specification cannot be met. Each gate's output is go, kill, hold or recycle. Criteria wording is EUTECNIQ's proposal and would be approved by its board before use.
Cooper RG. Stage-gate systems: a new tool for managing new products. Business Horizons. 1990;33(3):44–54.
Move the pass rates. Each stage costs more per candidate than the one before, so a candidate killed at validation has consumed most of its budget. The defaults (every gate passes half; costs 1, 5 and 15) are round numbers chosen to show the arithmetic, not data about botanical programs or EUTECNIQ.
Each chance node multiplies the value behind it by its probability; each stage subtracts its cost. Rolling back from the right gives the expected value of starting today, in relative units. With the illustrative defaults each stage has the same expected cost (10), so starting is worth 20 and breaks even at a launch value of 240.
The 20-year term runs from the first non-provisional or PCT filing, not from launch. Only products that needed premarket approval can recover part of it; dietary supplements cannot. Move the launch year.
Isolating a natural compound is not an invention: U.S. law excludes products of nature and laws of nature from patent eligibility, so protection shifts to formulations, processes and know-how that EUTECNIQ would engineer around the plant. EUTECNIQ owns no patents; the founder's patents are assigned to a prior employer. The six protection types and their terms are charted under background and new IP above.
A patent gives its owner the right to exclude others; it does not clear the owner's own product of other people's patents. Patents are territorial, so the search is run for each launch country and each product configuration.
A redesigned product is mapped again from step 3. The workflow runs before each development commitment and again before launch, for each new country or formulation.
Each step ends with an acceptance criterion agreed before the work starts. Process scale-up is on the process engineering page.
| Step | Owner | Acceptance criterion | Rule or reference |
|---|---|---|---|
| License or supply agreement | Both | Scope, field, territory, payments, data rights and reference rights are signed | Contract; 35 U.S.C. 261 for patent rights |
| Quality agreement | Both | Each party's responsibilities for testing, release, deviations, complaints and changes are written and signed | FDA guidance on quality agreements (drugs, 2016); 21 CFR 111.1: anyone who manufactures, packages, labels or holds a supplement is subject to Part 111 |
| Technology package | Sending site | Process description, specifications, methods, raw-material sources and known risks are complete and approved | 21 CFR 111.70 (specifications) |
| Analytical method transfer | Both | Results from a pre-approved protocol meet predetermined acceptance criteria (comparative testing, covalidation, revalidation or a justified waiver) | USP general chapter <1224> Transfer of Analytical Procedures |
| Supplier and material qualification | Receiving site | At least one identity test of each dietary ingredient before use; other components may rely on a supplier's certificate of analysis only after the supplier is qualified and periodically re-confirmed | 21 CFR 111.75(a) |
| Confirmation batches | Receiving site | Batches made at the receiving site meet every specification | 21 CFR 111.70, 111.75 |
| Comparability review | Both | Chemical fingerprint and impurity profile equivalent to the reference batches; differences explained | EUTECNIQ proposal; see NDIN on identity of the ingredient |
| Routine release and change control | Receiving site | Quality releases each lot against approved specifications; every change is assessed before it is made | 21 CFR Part 111 (supplements) or Part 117 (food) |
21 CFR 111.1, 111.70, 111.75 (eCFR); U.S. FDA. Contract Manufacturing Arrangements for Drugs: Quality Agreements. Guidance for Industry, November 2016; USP general chapter <1224>. The drug guidance is cited for structure; supplement firms are bound by Part 111, not by drug guidance.
What each function owes at each phase, how gates decide, why late attrition is expensive, how long patent protection lasts, and how a receiving site proves it can make the product.
Send the ingredient or technology, intended use, format, field and territory. A first reply would say whether there is a fit and propose a mutual NDA.